Published 01-25-17
Issued by Novartis
Novartis has published its Corporate Responsibility (CR) Performance Report for 2016. This year’s report provides even more context on the company’s CR performance, as well as views and comments on trends and challenges within the healthcare industry.
Novartis has published its Corporate Responsibility (CR) Performance Report for 2016. This year’s report provides even more context on the company’s CR performance, as well as views and comments on trends and challenges within the healthcare industry.
This is the fourth consecutive year Novartis has published an annual CR Performance Report. In 2016, we again structured our report in accordance with the Global Reporting Initiative’s (GRI) G4 guidelines, with disclosure at “comprehensive” level.
In 2016, Novartis improved its standing in several key corporate responsibility rankings. This includes the Access to Medicine Index, where Novartis ranked #3, up from fourth in 2014 and seventh in 2012, and we received an A- rating and were recognized among category leaders in healthcare in the 2016 CDP Climate Score.
Highlights of Novartis CR achievements in 2016 include:
Download the Novartis 2016 CR Performance Report
Share your feedback: corporate.responsibility@novartis.com
For more information on our corporate responsibility activities, visit our website.
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.